Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Status:
Not yet recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Phase 1, single-arm, open-label, dose escalating and expansion clinical trial to evaluate the
safety, tolerability, pharmacokinetic and preliminary efficacy of Lurbinectedin (PM01183) for
injection in patients with advanced solid tumors